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Abstract: Anti-Hu antibodies are directed against lung cancer cell
antigens. The anti-tumor effect of anti-Hu antibodies has been
suggested by several studies demonstrating that patients presenting
with anti-Hu antibodies have a longer survival. In this case report,
we suggest that the immunology of HuAb paraneplastic syndrome
by itself could induce tumor response.
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CASE REPORT
Anti-Hu antibodies are responsible for lung cancer
associated cerebellar ataxia and peripheral neuropathy. We
herein report the case of a woman presenting with anti-Hu
antibodies (HuAb)-related neuronopathy and non-small cell
lung cancer. Spontaneous disappearance of hilar tumor in-
volvement with concomitant impairment of neurological
symptoms suggests a putative efficacy of patient’s immunity
against non-small cell lung cancer.
A 75-year-old woman with a long history of type I
diabetes and tobacco consumption was admitted in December
2004 to the neurological department of the Nıˆmes Academic
Hospital (France) because of a subacute ataxia. Initial exam-
ination showed generalized areflexia and massive propriocep-
tive ataxia with pseudo-choreic arm movements. Electromyo-
graphy demonstrated lack of nerve sensory action potential
and significant decrease in motor potentials. Conduction
velocity examinations were normal. Cerebrospinal fluid study
was normal. Serum and cerebrospinal fluid HuAb detection
confirmed the paraneoplastic origin of the symptoms. A
tumor involving the right hilum was demonstrated by means
of a computed tomography scan (Figure 1A), and high fluo-
rine-18 deoxyglucose uptake as shown on positron emission
tomography scan (Figure 2A) precipitated the performance of
a fine-needle transbronchial biopsy. The procedure demon-
strated a non-small cell lung cancer of the squamous cell
histological subtype. Brain computed tomography scan and
magnetic resonance imaging were normal; particularly, nei-
ther metastasis nor cerebellum atrophy was found. The pa-
tient was denied surgery because her poor physiological
condition was thought to be incompatible with pulmonary
resection. Neither radiotherapy nor chemotherapy was initi-
ated because of the patient’s poor performance status of 3 and
a 12% body mass weight loss. A joint follow-up by neurology
and thoracic oncology units was proposed. In December
2005, the clinical examination detected a worsening of the
ataxia. HuAb was still detected in the serum, and the patient
was referred for plasmapheresis. Nevertheless, a new com-
puted tomography scan (Figure 1B) of the chest, abdomen,
and brain did not show any evidence of disease, and complete
remission of formerly histologically proven gross tumor in-
volvement was observed. A new positron emission tomogra-
phy scan performed in March 2006 did not demonstrate
significant uptake of fluorine-18 deoxyglucose (Figure 2B).
In May 2006, 18 months after HuAb paraneoplastic syn-
drome associated with non-small cell lung cancer had been
diagnosed, a new computed tomography of the chest con-
firmed a complete remission. Despite therapy using plasma-
pheresis, begun in January 2006, the patient remains severely
disabled with persistent and continuous weight loss.
DISCUSSION
The HuAb is directed against RNA-associated neuronal
proteins and is known to cause paraneoplastic encephalomy-
elitis/sensory neuronopathy syndrome, mostly when associ-
ated with small cell lung cancer.1 Anti-Hu paraneoplastic
syndromes, such as cerebellar ataxia or peripheral neuropa-
thy, might be the first clinical manifestation of human ma-
lignancies.2 This presentation has been observed in small cell
lung cancer and non-small cell lung cancer,3 cancer of the
breast and uterus, and both non-Hodgkin’s and Hodgkin’s
lymphomas.4,5 In some case reports, determining which ma-
lignant disease was responsible for these paraneoplastic syn-
dromes has been difficult or impossible. In addition, the
disease might be so difficult to detect that patient could die of
neurological complications, whereas small cell lung cancer
remains nearly undetectable at minimal tumor burden.2 One
can hypothesize that patients with anti-Hu antibodies without
demonstrable lung cancer are those for whom immunity
against the disease may have reduced the tumor to an unde-
tectable level. Our case report could be considered to favor
this hypothesis.
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Several studies have been undertaken to determine
whether patients with small cell lung cancer with detect-
able serum HuAb at the time of diagnosis have a particular
prognosis compared with patients without this immunolog-
ical feature. It has been suggested that patients with
paraneoplastic encephalomyelitis have a higher probability
of survival at 30 months compared with similar patients
without that clinical feature.6 In a prospective study, pa-
tients with small cell lung cancer were tested for the serum
HuAb determined by immunoblot of purified Hu antigen;
up to 16% of patients had a detectable level of anti-Hu
antibodies.7 HuAb was associated with limited disease
stage (59.3% versus 38.6%; p  0.047), complete response
to therapy (55.6% versus 19.6%; p  0.001), and longer
survival (14.9 versus 10.2 months; p  0.018). In a logistic
regression analysis, HuAb status was an independent pre-
dictor of complete response induction.7 Our case report
suggests that the immunology of HuAb paraneplastic syn-
drome itself could partially explained the better response
rate usually associated with treatment of patients with lung
cancer who present with a high serum HuAb level. The
probability of achieving a complete response was more
than five times greater for HuAb-positive versus HuAb-
negative patients (95% odds ratio, 5.4). In contrast with
small cell lung cancer, complete remission among patients
with non-small cell lung cancer is a rare event, particularly
long-term remission, which reinforces the peculiarity of
this case report.
Most patients with lung cancer and HuAb-associated
paraneoplastic encephalomyelitis die of neurological compli-
cations rather than tumor progression. Fortunately, the patient
presented in this report is still alive without evidence of lung
cancer 18 month after the diagnosis of an otherwise untreated
lung cancer. However, the vital prognosis remains poor
because of the slow and ineluctable progression of neurolog-
ical symptoms.
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FIGURE 2. (A) Fluorine-18 deoxyglucose-positron emission tomography scan performed at the time of histological diagno-
sis. (B) Fluorine-18 deoxyglucose-positron emission tomography scan performed at 1-year follow-up.
FIGURE 1. (A) Computed tomog-
raphy scan of the chest. Right hilum
involvement was demonstrated at
the time of diagnosis. (B) Computed
tomography scan performed at
1-year follow-up. Complete remis-
sion is observed whereas the patient
had received palliative care only.
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